Cloudbreak Newly announced an exclusive licensing and cooperation agreement for Xibutinib (EVER001).

• Everest Medicines and Travere Therapeutics have entered into an exclusive licensing and collaboration agreement, granting Travere Therapeutics exclusive development and commercialization rights to EVER001 (civorebrutinib) outside of Greater China and certain Southeast Asian countries.
• Under the agreement, Everest Medicines will receive an upfront payment of $112.5 million and is eligible to receive up to $1.03 billion in development, regulatory, and commercial milestone payments across up to five indications. Additionally, the company will receive tiered royalties ranging from high single-digit to double-digit percentages based on future annual net sales of EVER001.
• EVER001 is Everest Medicines’ next-generation, covalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor, with the development potential of a “pipeline-in-a-product.” It is expected to provide more treatment options for over 10 million patients worldwide suffering from diseases such as primary membranous nephropathy (PMN), IgA nephropathy, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis, demonstrating broad potential applications.
• This collaboration will accelerate the development of EVER001 across multiple immune-mediated kidney diseases. EVER001 is planned for clinical studies in indications such as PMN, immune-mediated FSGS, and MCD, with potential expansion into additional indications.

ShanghaiJune 2, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, hereinafter referred to as “the Company”), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, today announced that the Company has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX, hereinafter referred to as “Travere Therapeutics”). Under the agreement, Travere Therapeutics will obtain exclusive development and commercialization rights to EVER001 (civorebrutinib) outside of Greater China and certain Southeast Asian countries. This collaboration will accelerate the global clinical development and commercialization of EVER001, bringing innovative treatment options to kidney disease patients worldwide.

Under the agreement, Everest Medicines will receive an upfront payment of $112.5 million and is eligible to receive up to $1.03 billion in development, regulatory, and commercial milestone payments across up to five indications. Additionally, the company will receive tiered royalties ranging from high single-digit to double-digit percentages based on future annual net sales of EVER001. The transaction is subject to customary closing conditions and necessary regulatory procedures.

EVER001 is Everest Medicines’ next-generation, covalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor, with the development potential of a “pipeline-in-a-product.” Compared to covalent irreversible BTK inhibitors, EVER001, as a potential best-in-class product, maintains high activity while offering high selectivity, avoiding toxic side effects from sustained inhibition. Currently, no drug is approved globally for the treatment of primary membranous nephropathy. Existing conventional immunosuppressive therapies have limited efficacy, and some patients experience relapse after discontinuation, accompanied by certain adverse reactions, leaving unmet clinical needs.

Previously announced data from a Phase 1b/2a clinical study in Chinese PMN patients showed that EVER001 demonstrated rapid, deep, and durable immunological and clinical responses, with sustained benefits after discontinuation, high safety, and strong tolerability. These results support the potential of EVER001 in treating autoimmune glomerular diseases characterized by proteinuria.

EVER001 has development potential across various immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases are associated with glomerular damage caused by abnormal immune responses, leading to proteinuria and declining kidney function, which can progress to end-stage renal disease requiring dialysis or kidney transplantation in severe cases. EVER001 is expected to provide new treatment options for over 10 million patients worldwide. Currently, EVER001 is planned for clinical studies in indications such as PMN, immune-mediated FSGS, and MCD, with potential expansion into additional indications.

Yifang Wu, Chairman of Everest Medicines, said: “We are very pleased to enter into this collaboration with Travere Therapeutics. This partnership will accelerate the global development and commercialization of EVER001, further unlocking its clinical potential and commercial value in the field of autoimmune kidney diseases, bringing more innovative treatment options to patients worldwide.

As a potential best-in-class innovative drug, EVER001 has demonstrated positive potential in treating autoimmune kidney diseases such as primary membranous nephropathy. With its differentiated mechanism of action, EVER001 has the potential to expand into various autoimmune kidney diseases, continuously unlocking its clinical development potential.

The company consistently adheres to a dual-drive strategy of ‘BD collaboration + independent R&D,’ continuously advancing strategic business development and independent research and development, improving the global R&D system, and enhancing comprehensive competitiveness in the global innovative drug field. Travere Therapeutics has approved nephrology products in the United States and has accumulated extensive experience and mature capabilities in kidney disease drug development, registration, and commercialization. Both parties will leverage their respective strengths to jointly advance the global clinical development of EVER001 in primary membranous nephropathy, immune-mediated focal segmental glomerulosclerosis, and minimal change disease, bringing more breakthrough treatment options to patients worldwide.”

Dr. Eric Dube, President and CEO of Travere Therapeutics, said: “EVER001 is an important strategic addition to our rare kidney disease pipeline and offers significant synergistic value, with the potential to become a best-in-class therapy covering multiple immune-mediated rare kidney diseases. Rare kidney disease patients still face significant unmet clinical needs. We believe that the progress made in IgA nephropathy and FSGS is just the beginning of unlocking the potential in this therapeutic area. Travere Therapeutics is committed to driving significant innovation and breakthroughs in this field, leveraging our deep expertise in rare kidney diseases, mature R&D and commercialization capabilities, and ongoing commitment to patients, to bring more breakthrough treatment options.

As an oral reversible BTK inhibitor with differentiated advantages, EVER001 has shown encouraging proof-of-concept data in primary membranous nephropathy, and its mechanism of action can cover more disease areas such as immune-mediated focal segmental glomerulosclerosis and minimal change disease. We believe that EVER001 will bring more meaningful treatment breakthroughs for rare kidney disease patients, further reshaping the treatment landscape in this field.”

Primary membranous nephropathy is a common pathological type of adult nephrotic syndrome, with a rising prevalence in China, making it the second most common primary glomerulonephritis after IgA nephropathy¹. Currently, there are approximately 2 million patients with primary membranous nephropathy in China. Over one-third of primary membranous nephropathy patients eventually progress to end-stage renal disease, and there is an urgent global need for drugs that can improve treatment remission rates, reduce high relapse rates, and minimize chronic nephrotoxicity risks. In the future, Everest Medicines will collaborate with partners to accelerate the global development and value transformation of EVER001 and jointly advance subsequent R&D in other indications. The company will continue to enhance its comprehensive competitiveness in the global innovative drug field, bringing more breakthrough treatment options to patients in China and worldwide.

EVER001 was independently developed by Suzhou Sinovent Pharmaceuticals and, together with China Antibody (3681.HK), granted Everest Medicines the rights for development and commercialization in the field of kidney diseases globally in September 2021.

About EVER001 (civorebrutinib)
EVER001 capsules (also known as XNW1011) are a next-generation, covalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor, independently developed by Suzhou Sinovent Pharmaceuticals and, together with China Antibody (3681.HK), granted Everest Medicines the rights for development and commercialization in the field of kidney diseases globally in September 2021. The product is being developed globally for the treatment of kidney diseases. BTK is a key component of the B-cell receptor signaling pathway, regulating the survival, activation, proliferation, and differentiation of B lymphocytes. Therefore, targeting BTK with small molecule inhibitors is an effective option for treating B-cell lymphomas and autoimmune diseases.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, dedicated to meeting unmet medical needs in the global market. Everest Medicines’ management team has deep expertise and extensive experience in leading pharmaceutical companies in China and globally. The company has a commercial-scale global manufacturing base in Jiashan, Zhejiang Province, and has established a comprehensive GMP production quality management system in accordance with Chinese, U.S., and EU standards.

The company focuses on therapeutic areas such as autoimmune diseases, ophthalmology, acute and critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. It has built a commercialization platform integrating a full-channel commercial system and drug lifecycle commercialization capabilities. Based on its self-developed mRNA platform with global rights, the company continues to advance existing pipelines such as mRNA in vivo CAR-T and mRNA tumor vaccines, while expanding R&D capabilities through introductions and incubation of potential platforms, strengthening global layout, and accelerating international development. For more information, please visit the company’s official website: www.everestmedicines.com.

About Travere Therapeutics

Travere is a biopharmaceutical company with a mission of “In Rare For Life.” The team works together day in and day out to help patients, families, and caregivers from diverse backgrounds navigate the challenges of living with rare diseases. On this path, Travere understands that the need for treatment options is urgent, so Travere’s global team collaborates with the rare disease community to identify, develop, and deliver life-changing therapies. To fulfill this mission, Travere continuously seeks to understand the diverse perspectives of rare disease patients, bravely forging new paths to change their lives and bring hope—both today and in the future. For more information, please visit travere.com.

Forward-Looking Statements
The information released in this press release may contain certain forward-looking statements, based on the company’s or management’s current views, beliefs, and expectations regarding the company’s business operations and financial condition at the time the statements are made. These may use words such as “will,” “expect,” “predict,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “confident,” and other similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to various factors and assumptions, including changes and developments in our business, competitive environment, political, economic, legal, and social conditions. The company, its subsidiaries, directors, officers, advisors, and agents do not and disclaim any obligation to update the forward-looking statements contained in this release to reflect the latest information, future projects, or circumstances after the date of this press release, unless required by law.